Table 1 Correlation of p300 expression with patients' clinicopathologic features in primary hepatocellular carcinomas

Age (years)

0.267

   ≤ 47.7^b

59

28 (47.5%)

31 (52.5%)

   >47.7

64

35 (54.7%)

29 (45.3%)

Sex

0.564

   Male

107

55 (51.4%)

52 (48.6%)

   Female

16

8 (50.0%)

8 (50.0%)

Etiology

0.295

   HBV

97

48 (49.5%)

49 (50.5%)

   HCV

8

3 (37.5%)

5 (62.5%)

   None

18

12 (66.7%)

6 (33.3%)

AFP (ng/ml)

0.000

   ≤ 20

68

46 (67.6%)

22 (32.4%)

   >20

55

17 (30.9%)

38 (69.1%)

Liver cirrhosis

0.334

   Yes

87

47 (54.0%)

40 (46.0%)

   No

36

16 (44.4%)

20 (55.6%)

Tumor size (cm)

0.000

   ≤ 5

76

50 (65.8%)

26 (34.2%)

   >5

47

13 (27.7%)

34 (72.3%)

Tumor multiplicity

0.012

   Single

85

50 (58.8%)

35 (41.2%)

   Multiple

38

13 (34.2%)

25 (65.8%)

Differentiation

0.036

   Well

15

12 (80.0%)

3 (20.0%)

   Moderate

70

36 (51.4%)

34 (48.6%)

   Poor

32

14 (43.8%)

18 (56.3%)

   Undifferentiated

6

1 (16.7%)

5 (83.3%)

Stage

0.015

   I

12

10 (83.3%)

2 (16.7%)

   II

49

27 (55.1%)

22 (44.9%)

   III

48

23 (47.9%)

25 (52.1%)

   IV

14

3 (21.4%)

11 (78.6%)

Vascular invasion

0.130

   Yes

55

24 (43.6%)

31 (56.4%)

   No

68

39 (57.4%)

29 (42.6%)

Relapse

0.182

   Yes

42

18 (42.9%)

24 (57.1%)

   No

81

45 (55.6%)

36 (44.4%)

Ki67 expression

0.002

   Low

68

44 (64.7%)

24 (35.3%)

   High

50

18 (36.0%)

32 (64.0%)